Access Vascular, Inc.
Medical device company focused on developing and commercializing venous access devices that incorporate our novel hydrophilic materials
 

The Story:

Access Vascular is developing a peripherally inserted central catheter using our novel bulk hydrophilic biomaterial that prevents blood component accumulation otherwise known as Thrombus. Within seconds after a catheter is placed into the bloodstream, blood proteins (fibrinogen and collagen) and host cells (platelets) begin to deposit on the device surface. Thrombus formation restricts flow through and around the device, which adversely affects infusion and aspiration, often requiring the use of expensive thrombolytic medications or even device replacement to resolve the blockage.

Our technology is not recognized by the body as a foreign material and therefore does not trigger the body’s thrombotic response, the initial trigger to a cascade of events that lead to catheter occlusion and bacterial colonization.

Product: For our first product, the HydroPICC, we changed the core material from which conventional PICCs are made, switching from polyurethanes to our proprietary bulk hydrophilic material. The HydroPICC is designed to eliminate the need for further modification with additives or coatings to achieve its anti-thrombogenic properties. Our technology is not recognized by the body as a foreign material and therefore does not trigger the body’s thrombotic response, the initial trigger to a cascade of events that lead to catheter occlusion and bacterial colonization. The net result will be improved procedural efficiencies, a higher quality of care and improved reimbursement.

 

Efficacy: Access Vascular has completed benchtop biocompatibility and preclinical studies, and the material has proven to be reduce thrombogenicity. Our testing has demonstrated the potential for superior clinical outcomes and lower healthcare costs compared with existing technologies.